May 2006
Volume 47, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2006
The Effect of a Topical NSAID, Ketorolac Tromethamine 0.4%, on Quality of Vision With a Multifocal IOL
Author Affiliations & Notes
  • E. Donnenfeld
    Department, North, Rockville, NY
  • K. Solomon
    Ophthalmology, MUSC, Charleston, SC
  • R. Chu
    Chu Vision Institute, Edina, MN
  • Footnotes
    Commercial Relationships  E. Donnenfeld, Allergan, C; K. Solomon, Allergan, C; R. Chu, Allergan, F.
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 617. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      E. Donnenfeld, K. Solomon, R. Chu; The Effect of a Topical NSAID, Ketorolac Tromethamine 0.4%, on Quality of Vision With a Multifocal IOL . Invest. Ophthalmol. Vis. Sci. 2006;47(13):617.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate the effect of a topical NSAID on quality of vision and macula thickening with a multifocal IOL

Methods: : A multicenter, randomized, masked prospective clinical trial to evaluate the effect of ketorolac tromethamine 0.4% four times a day for 3 days preop and 3 weeks postop versus placebo on the quality of vision in 50 patients bilaterally implanted with the ReSTOR IOL. UCVA, BCVA, mesopic and photopic contrast sensitivity under high contrast and low contrast illumination were measured unilaterally at 2 weeks and 3 months following second eye implantation. In addition patients will perform a life style and life style vision questionnaire at 3 months.

Results: : At 2 weeks following the second eye implantation, the patients who received the ketorolac tromethamine 0.4% had statistically significant improved UCVA, BCVA, and contrast sensitivity as compared to patients receiving placebo. Life style and life style vision questionnaire at 3 months supported improved patient satisfaction with their multifocal IOL when they received topical ketorolac tromethamine 0.4% versus placebo.

Conclusions: : The preoperative and postoperative use of ketorolac tromethamine 0.4% significantly improved visual outcomes in patients bilaterally implanted with the ReSTOR multifocal IOL.

Keywords: intraocular lens • quality of life 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×